Your browser doesn't support javascript.
Radiomorphological signs and clinical severity of SARS-CoV-2 lineage B.1.1.7.
Simon, Judit; Grodecki, Kajetan; Cadet, Sebastian; Killekar, Aditya; Slomka, Piotr; Zara, Samuel James; Zsarnóczay, Emese; Nardocci, Chiara; Nagy, Norbert; Kristóf, Katalin; Vásárhelyi, Barna; Müller, Veronika; Merkely, Béla; Dey, Damini; Maurovich-Horvat, Pál.
  • Cadet S; Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA.
  • Killekar A; Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA.
  • Slomka P; Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA.
  • Zara SJ; Medical Imaging Centre, Semmelweis University, Budapest, Hungary.
  • Nardocci C; Medical Imaging Centre, Semmelweis University, Budapest, Hungary.
  • Nagy N; Medical Imaging Centre, Semmelweis University, Budapest, Hungary.
  • Kristóf K; Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary.
  • Vásárhelyi B; Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary.
  • Müller V; Department of Pulmonology, Semmelweis University, Budapest, Hungary.
  • Merkely B; MTA-SE Cardiovascular Imaging Research Group, Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • Dey D; Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA.
BJR Open ; 4(1): 20220016, 2022.
Article in English | MEDLINE | ID: covidwho-2281533
ABSTRACT

Objective:

We aimed to assess the differences in the severity and chest-CT radiomorphological signs of SARS-CoV-2 B.1.1.7 and non-B.1.1.7 variants.

Methods:

We collected clinical data of consecutive patients with laboratory-confirmed COVID-19 and chest-CT imaging who were admitted to the Emergency Department between September 1- November 13, 2020 (non-B.1.1.7 cases) and March 1-March 18, 2021 (B.1.1.7 cases). We also examined the differences in the severity and radiomorphological features associated with COVID-19 pneumonia. Total pneumonia burden (%), mean attenuation of ground-glass opacities and consolidation were quantified using deep-learning research software.

Results:

The final population comprised 500 B.1.1.7 and 500 non-B.1.1.7 cases. Patients with B.1.1.7 infection were younger (58.5 ± 15.6 vs 64.8 ± 17.3; p < .001) and had less comorbidities. Total pneumonia burden was higher in the B.1.1.7 patient group (16.1% [interquartile range (IQR)6.0-34.2%] vs 6.6% [IQR1.2-18.3%]; p < .001). In the age-specific analysis, in patients <60 years B.1.1.7 pneumonia had increased consolidation burden (0.1% [IQR0.0-0.7%] vs 0.1% [IQR0.0-0.2%]; p < .001), and severe COVID-19 was more prevalent (11.5% vs 4.9%; p = .032). Mortality rate was similar in all age groups.

Conclusion:

Despite B.1.1.7 patients were younger and had fewer comorbidities, they experienced more severe disease than non-B.1.1.7 patients, however, the risk of death was the same between the two groups. Advances in knowledge Our study provides data on deep-learning based quantitative lung lesion burden and clinical outcomes of patients infected by B.1.1.7 VOC. Our findings might serve as a model for later investigations, as new variants are emerging across the globe.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Variants Language: English Journal: BJR Open Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Variants Language: English Journal: BJR Open Year: 2022 Document Type: Article